A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining a growing number of biotechs in the area that are based on an emerging field in cell biology.
Faze Medicines will work on “biomolecular condensates,” which it believes can be studied to develop drugs that could slow, halt, or reverse certain diseases. Condensates are membrane-less organelles, or clusters of molecules such as proteins and nucleic acids, that help cells perform vital functions.
Faze will prioritize its existing programs that target amyotrophic lateral sclerosis, known as ALS, and myotonic dystrophy 1, but it has several other programs in development, said Rachel Meyers, the company’s chief scientific officer, in an interview.
